Skip to main content

Table 1 The correlations among p53 codon 72 variants and various patient characteristics

From: Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment

  Patients (n = 99) codon 72 (No.4) p value
CC (n = 28) GG (n = 38) CG (n = 33)  
n % n % n % n %
Age (n = 99)          0.035*
  > 60 58 58.59% 21 75.00% 23 60.53% 14 (42.4%)  
60 41 41.41% 7 25.00% 15 39.47% 19 (57.6%)  
Gender (n = 99)          0.819
 Male 43 43.43% 13 46.43% 15 39.47% 15 45.45%  
 Female 56 56.57% 15 53.57% 23 60.53% 18 54.55%  
Tumor number (n = 99)          0.442
 Solitary 78 78.79% 20 71.43% 30 78.95% 28 84.85%  
 Multiple 21 21.21% 8 28.57% 8 21.05% 5 15.15%  
Tumor size (n = 99)          0.138
  > 3 cm 12 12.12% 6 21.43% 2 5.26% 4 12.12%  
3 cm 87 87.88% 22 78.57% 36 94.74% 29 87.88%  
Tumor occurrence (n = 99)          0.531
 Primary 78 78.79% 20 71.43% 31 81.58% 27 81.82%  
 Recurrence 21 21.21% 8 28.57% 7 18.42% 6 18.18%  
Bevacizumab (n = 99)          0.179
 No used 45 45.45% 13 46.43% 21 55.26% 11 33.33%  
 Used 54 54.55% 15 53.57% 17 44.74% 22 66.67%  
LO-16 nt (n = 76, DNA sequencing)
(No. 2; rs17878362)
         0.804
 Heterozygote loss 6 (7.9%) 3 (13.6%) 0 (0.0%) 3 (12.5%)  
 Homozygote loss 70 (92.1%) 19 (86.4%) 30 30(100%) 21 (87.5%)  
11,299 (No.3) (n = 76, DNA sequencing)          0.007**
 CC 65 85.53% 15 68.18% 30 100.00% 20 83.33%  
 CA 8 10.53% 4 18.18% 0 0.00% 4 16.67%  
 AA 3 3.95% 3 13.64% 0 0.00% 0 0.00%  
  1. Chi-squared test. *p < 0.05, **p < 0.001, Statistical significance